Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline Lifts Dividend 6% to Yield 4.5%

By Mark Rogers - Apr 24, 2013 at 2:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GlaxoSmithKline plans to sell Lucozade and Ribena.

LONDON -- The shares of GlaxoSmithKline (GSK -1.19%) (GSK -1.22%) were flat at 1,676 pence early this afternoon after the FTSE pharmaceutical giant lifted its first-quarter dividend by 6%.

Glaxo declared a dividend of 18 pence per share for the quarter, compared to 17 pence per share last year.

The company reported sales had declined 2% to 6.4 billion pounds during January, February and March, which reflected the disposal of 17 over-the-counter products since last year. Quarterly profits dropped 26% to 1.6 billion pounds.

Glaxo said it expected core EPS growth of between 3% and 4%, and turnover growth of around 1%, during 2013.

The firm added that it would target share repurchases of between 1 billion pounds and 2 billion pounds next year as well.

Glaxo also confirmed a restructure of its research and development activities remained on course to deliver total annual savings of 1 billion pounds by 2016.

Chief executive Sir Andrew Witty commented:

This quarter marks continued strategic delivery for GSK with sales and earnings in line with our expectations, significant pipeline progress and further growth in our returns to shareholders through a 6% increase in the dividend. We are also announcing additional measures to improve the Group's focus and long term growth profile.

Sir Andrew also revealed Glaxo is to put its Lucozade and Ribena drinks brands up for sale. He said a strategic review of the products had concluded "the tremendous growth potential of these iconic brands" could be "better leveraged" by other companies.

Glaxo is currently valued at 14 times expected earnings and offers a trailing twelve-month dividend yield of 4.5%.

On these figures, the Fool's top analysts have highlighted Glaxo as one of "5 Shares You Can Retire On," an exclusive wealth report that reviews five particularly attractive possibilities in the FTSE 100.

Including Glaxo, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends. Just click here for the reportm -- it's free.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.42 (-1.22%) $0.55
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$1,753.80 (-1.19%) $-21.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.